PetIQ, Inc. (PETQ)
USD 30.98
(-0.03%)
USD 30.98
(-0.03%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 2.13 Million USD | 104.38% |
| 2022 | -48.62 Million USD | -196.77% |
| 2021 | -16.38 Million USD | 79.78% |
| 2020 | -81.02 Million USD | -466.51% |
| 2019 | -14.3 Million USD | -1728.9% |
| 2018 | -782 Thousand USD | 77.61% |
| 2017 | -3.49 Million USD | -2.8% |
| 2016 | -3.39 Million USD | -151.89% |
| 2015 | -1.34 Million USD | 87.72% |
| 2014 | -10.98 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 14.9 Million USD | 185.25% |
| 2024 Q2 | 15.32 Million USD | 2.78% |
| 2023 Q3 | 451 Thousand USD | -95.24% |
| 2023 Q4 | -17.48 Million USD | -3977.38% |
| 2023 FY | 2.13 Million USD | 104.38% |
| 2023 Q2 | 9.46 Million USD | -2.38% |
| 2023 Q1 | 9.69 Million USD | 240.81% |
| 2022 Q3 | -49.57 Million USD | -1170.19% |
| 2022 FY | -48.62 Million USD | -196.77% |
| 2022 Q1 | 3.13 Million USD | 122.17% |
| 2022 Q4 | -6.88 Million USD | 86.1% |
| 2022 Q2 | 4.63 Million USD | 47.94% |
| 2021 Q1 | 2.03 Million USD | 119.51% |
| 2021 Q2 | 4.02 Million USD | 98.03% |
| 2021 Q3 | -7.9 Million USD | -296.27% |
| 2021 Q4 | -14.12 Million USD | -78.74% |
| 2021 FY | -16.38 Million USD | 79.78% |
| 2020 Q3 | -63.06 Million USD | -3234.8% |
| 2020 Q2 | -1.89 Million USD | 10.08% |
| 2020 Q1 | -2.1 Million USD | 80.84% |
| 2020 FY | -81.02 Million USD | -466.51% |
| 2020 Q4 | -10.41 Million USD | 83.48% |
| 2019 Q4 | -10.97 Million USD | -86.37% |
| 2019 FY | -14.3 Million USD | -1728.9% |
| 2019 Q3 | -5.89 Million USD | -254.39% |
| 2019 Q2 | 3.81 Million USD | 136.81% |
| 2019 Q1 | 1.61 Million USD | 146.37% |
| 2018 FY | -782 Thousand USD | 77.61% |
| 2018 Q1 | -2.02 Million USD | 37.92% |
| 2018 Q2 | 2.49 Million USD | 223.22% |
| 2018 Q3 | 2.22 Million USD | -11.12% |
| 2018 Q4 | -3.47 Million USD | -256.42% |
| 2017 Q4 | -3.26 Million USD | -1345.58% |
| 2017 Q1 | 4.28 Million USD | 225.99% |
| 2017 FY | -3.49 Million USD | -2.8% |
| 2017 Q2 | 6.07 Million USD | 41.81% |
| 2017 Q3 | -226 Thousand USD | -103.72% |
| 2016 Q1 | -305 Thousand USD | 0.0% |
| 2016 Q4 | -3.39 Million USD | -35.27% |
| 2016 Q3 | -2.51 Million USD | -520.77% |
| 2016 Q2 | 597 Thousand USD | 295.74% |
| 2016 FY | -3.39 Million USD | -151.89% |
| 2015 Q1 | 3.71 Million USD | 0.0% |
| 2015 FY | -1.34 Million USD | 87.72% |
| 2014 FY | -10.98 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -209.24 Million USD | 101.018% |
| Theratechnologies Inc. | -23.95 Million USD | 108.895% |
| Safety Shot Inc | -15.08 Million USD | 114.128% |
| Cosmos Health Inc. | -18.54 Million USD | 111.492% |
| Cronos Group Inc. | -73.96 Million USD | 102.881% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 100.213% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 105.05% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 56.906% |
| Universe Pharmaceuticals INC | -6.16 Million USD | 134.577% |
| ProPhase Labs, Inc. | -16.78 Million USD | 112.698% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | 144.074% |
| Dynavax Technologies Corporation | -6.38 Million USD | 133.354% |
| Radius Health, Inc. | -25.79 Million USD | 108.263% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | 168.775% |
| Alvotech | -551.73 Million USD | 100.386% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 147.292% |
| Alpha Teknova, Inc. | -36.78 Million USD | 105.794% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 101.526% |
| SCYNEXIS, Inc. | 67.04 Million USD | 96.821% |
| Harrow Health, Inc. | -24.41 Million USD | 108.73% |
| Biofrontera Inc. | -20.13 Million USD | 110.586% |
| DURECT Corporation | -27.62 Million USD | 107.714% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | -61.93% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 88.652% |
| OptiNose, Inc. | -35.48 Million USD | 106.006% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 91.09% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | 127.078% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | 133.937% |
| SIGA Technologies, Inc. | 68.06 Million USD | 96.869% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 82.261% |
| Shineco, Inc. | -22.44 Million USD | 109.493% |
| Phibro Animal Health Corporation | 2.41 Million USD | 11.796% |
| Procaps Group S.A. | 42.54 Million USD | 94.991% |
| TherapeuticsMD, Inc. | -10.27 Million USD | 120.734% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | 149.537% |
| Viatris Inc. | 54.7 Million USD | 96.104% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 147.292% |
| Rockwell Medical, Inc. | -8.43 Million USD | 125.252% |
| Incannex Healthcare Limited | -18.45 Million USD | 111.545% |
| Aytu BioPharma, Inc. | -15.84 Million USD | 113.45% |
| Tilray Brands, Inc. | -244.98 Million USD | 100.87% |
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 95.575% |
| Silver Spike Investment Corp. | 7.34 Million USD | 70.968% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 99.147% |
| Journey Medical Corporation | -3.85 Million USD | 155.308% |
| Alimera Sciences, Inc. | -20.13 Million USD | 110.585% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | 126.105% |
| Assertio Holdings, Inc. | -331.94 Million USD | 100.642% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | 132.324% |
| Embecta Corp. | 70.4 Million USD | 96.973% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 110.625% |
| Procaps Group, S.A. | 42.54 Million USD | 94.991% |
| PainReform Ltd. | -9.34 Million USD | 122.806% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 101.33% |
| Hempacco Co., Inc. | -13.12 Million USD | 116.235% |
| Talphera, Inc. | -18.39 Million USD | 111.583% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 94.921% |
| Alvotech | -551.73 Million USD | 100.386% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 99.348% |
| Kamada Ltd. | 8.28 Million USD | 74.276% |
| Indivior PLC | 2 Million USD | -6.55% |
| Currenc Group, Inc. | -15.3 Million USD | 113.922% |
| Evoke Pharma, Inc. | -7.79 Million USD | 127.348% |
| Flora Growth Corp. | -57.03 Million USD | 103.736% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 110.625% |
| Evolus, Inc. | -61.68 Million USD | 103.455% |
| HUTCHMED (China) Limited | 100.78 Million USD | 97.885% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 98.451% |
| Akanda Corp. | -32.27 Million USD | 106.603% |